| 000 | 01806 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516054635.0 | ||
| 264 | 0 | _c20120105 | |
| 008 | 201201s 0 0 eng d | ||
| 022 | _a1873-2399 | ||
| 024 | 7 |
_a10.1016/j.exphem.2011.09.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShuqing, Lü | |
| 245 | 0 | 0 |
_aUpregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. _h[electronic resource] |
| 260 |
_bExperimental hematology _cDec 2011 |
||
| 300 |
_a1117-8 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aBoronic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xbiosynthesis |
| 650 | 0 | 4 |
_aProteasome Endopeptidase Complex _xbiosynthesis |
| 650 | 0 | 4 |
_aPyrazines _xadministration & dosage |
| 650 | 0 | 4 |
_aThalidomide _xadministration & dosage |
| 650 | 0 | 4 | _aUp-Regulation |
| 700 | 1 | _aJianmin, Yang | |
| 700 | 1 | _aChongmei, Huang | |
| 700 | 1 | _aHui, Cheng | |
| 700 | 1 | _aWang, Jianmin | |
| 773 | 0 |
_tExperimental hematology _gvol. 39 _gno. 12 _gp. 1117-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.exphem.2011.09.003 _zAvailable from publisher's website |
| 999 |
_c21159725 _d21159725 |
||